曲美他嗪对经皮冠状动脉介入治疗术后SOD、MDA、hs-CRP和cTnI的影响  

Effect of trimetazidine on SOD,MDA,hs-CRP and cTnI of patients undergoing percutaneous coronary intervention

作　　者：马琦琳[1] 吉绍葵[1] 孔涛[1] 宁阳根[1] 

机构地区：[1]中南大学湘雅医院心内科,湖南长沙410008

出　　处：《中国现代医学杂志》2010年第17期2643-2645,2649,共4页China Journal of Modern Medicine

摘　　要：目的探讨曲美他嗪对经皮冠状动脉介入治疗(PCI)患者超氧化物歧化酶(SOD)、丙二醛(MDA)、血清高敏C-反应蛋白(hs-CRP)及肌钙蛋白(IcTnI)的影响。方法选择因冠状动脉狭窄病变需行PCI术的不稳定型心绞痛(UA)患者41例,随机分成两组。常规治疗基础上,术前3d加服曲美他嗪后行PCI术20例为曲美他嗪组,未服曲美他嗪行PCI术21例为常规治疗组。两组在行PCI术前3d、术后24h均检测血清SOD、MDA、hs-CRP和cTnI的水平。结果曲美他嗪组PCI术后24h较术前3d的hs-CRP、MDA和cTnI水平降低(P<0.01),SOD水平升高(P<0.01);常规治疗组PCI术后24h较术前3d的hs-CRP、MDA和cTnI水平升高(P<0.01),SOD水平降低(P<0.01);曲美他嗪组常较规治疗组术后24hhs-CRP、MDA和cTnI水平降低(P<0.01),SOD水平升高(P<0.01)。结论曲美他嗪能够抑制PCI术后炎症反应,减少膜脂质的过氧化损伤,从而减轻PCI术造成的心肌细胞损伤,预防再狭窄,为PCI术患者提供心脏保护。ObjectiveTo determine the effect of trimetazidine on SOD,MDA,hs-CRP and cTnI in the patients undergoing percutaneous coronary intervention（PCI）.Methods The study consisted of 41 patients with unstable angina who underwent elected PCI for stenotic lesions of the coronary artery.The patients were randomly assigned to either trimetazidine group or conventional one.Twenty cases taking trimetazidine 3 days before PCI surgery were enrolled into trimetazidine group,while twenty-one cases receiving conventional therapy without taking trimetazidine were enrolled into conventional therapy group.3 days before PCI and 24 hours after PCI,serum SOD,MDA,hsCRP and cTnI levels were detected in both groups.ResultsThe levels of CRP,MDA and cTnI 24 hours after PCI surgery were lower than those 3 days before PCI in trimetazidine group（P〈0.05）,but SOD level was higher（P〈0.05）.The levels of CRP,MDA and cTnI 24 hours after PCI were higher than those 3 days before PCI in the conventional therapy group（P〈0.05）,but SOD level was lower（P〈0.05）.Compared with the conventional therapy group,the levels of hs-CRP,MDA and cTnI in the trimetazidine group 24 hours after PCI surgery were lower（P〈0.05）,SOD level was higher（P〈0.05）.ConclusionTrimetazidine can inhibit the inflammatory response,reduce membrane lipid peroxidation injury,thereby reduce myocardial cell injury caused by PCI,prevent stenosis,and provide cardiac protection for PCI patients.

关 键 词：曲美他嗪 经皮冠状动脉介入治疗 超氧化物歧化酶 丙二醛 高敏C-反应蛋白 肌钙蛋白I 

分 类 号：R816.2[医药卫生—放射医学]